Results 21 to 30 of about 1,404,058 (313)

Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells [PDF]

, 2016
Cancer stem cells (CSCs) play an important role in tumor initiation, progression, therapeutic failure and tumor relapse. In this study, we evaluated the efficacy of the thiazole derivative 3-methylcyclopentylidene-[4-(4’-chlorophenyl)thiazol-2-yl ...
Buglioni, Simonetta, Carradori, Simone, DE LUCA, Teresa, De Maria, Ruggero, Del Bufalo, Donatella, Desideri, Marianna, DI MARTILE, Marta, Eramo, Adriana, Gabellini, Chiara, Mai, Antonello, Milella, MICHELE STANISLAW, Rotili, Dante, Secci, Daniela, Sette, Giovanni, Trisciuoglio, Daniela   +14 more
core   +8 more sources

Additional file 1: of A biomarker basing on radiomics for the prediction of overall survival in nonâ small cell lung cancer patients

, 2018
Table S1. Demographic Information of the patients. (DOCX 15 kb)
He, Bo, Zhao, Wei, Pi, Jiang-Yuan, Han, Dan, Jiang, Yuan-Ming, Zhang, Zhen-Guang   +5 more
openaire   +1 more source

Dry Small Pleural Dissemination of Adenocarcinoma of the Lung Preoperatively Detected by PET/CT: A Report of Two Cases [PDF]

, 2008
Dry pleural dissemination in non-small cell lung cancer, defined as solid pleural metastasis of lung cancer without pleural eff usion, is a condition occurring in T4 lung cancer.
Aoe, Motoi, Date, Hiroshi, Okutani, Daisuke, Oto, Takahiro, Sano, Yoshifumi, Toyooka, Shinichi, Yamane, Masaomi   +6 more
core   +1 more source

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

New England Journal of Medicine, 2023
BACKGROUND Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone.
H. Wakelee, M. Liberman, T. Kato, M. Tsuboi, Se-Hoon Lee, Shugeng Gao, Keke Chen, C. Dooms, M. Majem, E. Eigendorff, G. Martinengo, O. Bylicki, D. Rodríguez-Abreu, J. Chaft, S. Novello, Jing Yang, S. Keller, A. Samkari, J. Spicer   +18 more
semanticscholar   +1 more source

Potential role of immunotherapy in advanced non-small-cell lung cancer [PDF]

, 2016
Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib ...
Antoniou, Georgios, Catarina, Paulo Esrom, De Mello, Ramon Andrade, Nadine, Sara, Veloso, Ana Flavia   +4 more
core   +3 more sources

Additional file 1: of Development of the Japanese version of an information aid to provide accurate information on prognosis to patients with advanced nonâ small-cell lung cancer receiving chemotherapy: a pilot study

, 2018
Information Aid for First-line Chemotherapy. (DOCX 42Â kb)
Nakano, Kikuo, Kitahara, Yoshihiro, Mineyo Mito, Seno, Misato, Sunada, Shoji   +4 more
openaire   +1 more source

Non small-cell lung cancer with metastasis to thigh muscle and mandible: two case reports [PDF]

, 2013
INTRODUCTION: Lung cancer is the leading cause of cancer-related death in Europe and the US. Isolated metastases to skeletal muscle and the mandible are very uncommon. CASE PRESENTATION: This report presents two cases.
Agnese Montanino, Domingo Alberti, Fabrizio Cammarota, Francesca Maria Giugliano, Franco Fulciniti, Giampaolo De Palma, Giovanna Guida, Luciano Iadanza, Maria Mormile, Paolo Muto, Vincenzo Ravo   +10 more
core   +1 more source

Chinese Expert Consensus on the Standardized Diagnosis and Treatment of 
Non‑small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)

Chinese Journal of Lung Cancer
The standard clinical practice of managing the non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations was elaborated in Chinese expert consensus on non‑small cell lung cancer with EGFR exon ...
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee
doaj   +1 more source

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [PDF]

, 2004
BACKGROUND: Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).
Bell, D. W., Brannigan, B. W., Christiani, D. C., Gurubhagavatula, S., Haber, D. A., Haluska, F. G., Harris, P. L., Haserlat, S. M., Louis, D. N., Lynch, T. J., Okimoto, R. A., Settleman, J., Sordella, R., Supko, J. G.   +13 more
core   +1 more source

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

New England Journal of Medicine, 2022
BACKGROUND Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 ...
P. Jänne, Gregory Riely, S. Gadgeel, R. Heist, S. Ou, J. Pacheco, M. Johnson, J. Sabari, Konstantinos Leventakos, E. Yau, L. Bazhenova, M. Negrão, N. Pennell, Jun Zhang, K. Anderes, H. Der-Torossian, T. Kheoh, K. Velastegui, X. Yan, J. Christensen, R. Chao, A. Spira   +21 more
semanticscholar   +1 more source